PROCESS OF PRODUCING Sindora supa ANTI-DIABETES DRUG

The present utility model relates in general to a process of producing an herbal supplement for the prevention of diabetes mellitus. Specifically, it relates to the use of Sindora supa (S. supa) in producing a stable and standardized tablet dosage form of an anti-diabetes drug through alpha-glucosidase inhibiting activity. The anti-diabetes drug composition comprises of: approximately 44-49 pcnt weight Sindora supa ethanolic extract; approximately 44-49 pcnt weight diluent preferably colloidal silica; approximately 1.78-1.96 pcnt weight disintegrant preferably crospovidone; approximately 4.44-4.90 pcnt binder preferably microcrystalline cellulose; and, approximately 0.45-0.49 pcnt flow activator preferably magnesium stearate. It is made by a process comprising: collecting and preparing raw materials; drying and milling the raw materials; subjecting the raw materials to ethanolic extraction; subjecting the ethanolic extract solution to rotary evaporation; subjecting the ethanolic extract to lyophilization; subjecting the ethanolic extract to quality control; conducting pre-formulation tests; dissolving the ethanolic extract in equal amounts of ethanol and colloidal silica; drying and sieving the silicated extract; mixing the silicated extract with microcrystalline cellulose, crospovidone, and magnesium stearate; subjecting the mixture to dry granulation; sieving and weighing the granular mixture; compressing the granular mixture into tablet dosage form; and, subjecting the tablets to quality control tests.